SAMe Joint 400.

S-adenosylmethionine is made from methionine and ATP by methionine adenosyltransferase. Methionine supply is the upstream input to everything SAMe does.

Methionine adenosyltransferase requires magnesium and ATP to attach the adenosyl group onto methionine. Low magnesium status limits how much SAMe the body forms from a given methionine pool.

Once SAMe gives up its methyl group it becomes homocysteine, which methionine synthase remethylates using a B12-bound methyl group. Without B12 that recycling loop stalls and homocysteine accumulates.

5-methyltetrahydrofolate is the methyl donor that methionine synthase hands to B12 and then to homocysteine. Folate and B12 work as a pair on the step that regenerates methionine after SAMe is spent.

Cystathionine beta-synthase and cystathionine gamma-lyase are both pyridoxal-5-phosphate enzymes, and they route homocysteine onward to cysteine. B6 status decides whether the downstream arm of the SAMe cycle stays open.

MTHFR carries FAD, which riboflavin supplies, and it makes the 5-methyl folate used to remethylate homocysteine. Riboflavin status therefore feeds the same recycling loop that keeps SAMe replenished.

Betaine-homocysteine methyltransferase remethylates homocysteine using betaine rather than folate, a second independent path back to methionine. It carries load when the folate route is limited.

Phosphatidylethanolamine N-methyltransferase consumes three SAMe methyl groups per phosphatidylcholine molecule made. Dietary choline lets the body use the direct route instead, leaving more methyl groups for other transfers.

Guanidinoacetate methyltransferase is one of the largest single consumers of SAMe methyl groups in the body. Supplemental creatine lowers endogenous synthesis and so lowers that methyl demand.

Glycine N-methyltransferase uses surplus SAMe to methylate glycine into sarcosine, which is how the body buffers a high methylation ratio. Glycine availability lets that buffer operate.

Homocysteine leaving the SAMe cycle through transsulfuration becomes cysteine, the rate-limiting amino acid for glutathione synthesis. The methylation cycle and the glutathione pool are connected at that junction.

NAC supplies cysteine directly, easing demand on the transsulfuration route that pulls homocysteine out of the methionine cycle. That keeps more of the cycle available for methyl transfer.

SAMe raises monoamine turnover through methylation-dependent steps, and 5-HTP feeds serotonin synthesis directly. Stacking them adds two pushes on the same signalling system, which is a settled caution rather than a benefit.

Hypericum constituents slow monoamine reuptake while SAMe supports monoamine methylation and turnover. The combined effect on serotonergic tone is additive and is the reason the pair is flagged rather than recommended.

Serine hydroxymethyltransferase transfers a carbon from serine to tetrahydrofolate, producing the 5,10-methylene folate that is reduced to the methyl folate used to remethylate homocysteine. Methionine regenerated that way is what the MAT enzymes convert back to S-adenosylmethionine using ATP. Serine supply therefore sits two steps upstream of the molecule itself.

After a methyl group is donated, the remaining S-adenosylhomocysteine is hydrolysed to homocysteine, which can be committed to the transsulfuration branch and condensed with serine to form cystathionine and then cysteine. Cysteine is the rate-limiting input to glutathione and a source of inorganic sulfate. That makes cysteine a downstream product rather than a cofactor.

Cysteine can be oxidised to cysteine sulfinate and decarboxylated to hypotaurine and then taurine. So taurine and the methyl-donor pathway draw on the same sulfur stream. This is pathway architecture, not a combination study.

Glycosaminoglycan chains in cartilage carry sulfate esters, and inorganic sulfate for that sulfation is generated largely from cysteine oxidation. Both a methyl-donor sulfonium compound and a small organosulfur molecule feed sulfur into that pool, though by different routes. Which fraction of either actually reaches glycosaminoglycan sulfation in a person has not been quantified here.

Building a sulfated glycosaminoglycan needs both the amino sugar backbone and activated sulfate as PAPS. Glucosamine supplies the first, and sulfur-donor metabolism supplies the second. The pair is often formulated together for that complementary reason; a trial of the combination is not in this candidate set, so it stands on biochemistry.

Chondroitin arrives as an intact sulfated polymer, largely depolymerised before absorption, while methyl-donor metabolism contributes to the sulfate pool the body uses to sulfate its own newly made chains. The two supply the same tissue component from opposite ends. No combination evidence is available here.

Cartilage matrix is a collagen network with proteoglycan trapped inside it, so the two components are not interchangeable. A peptide source of collagen amino acids and a sulfur-donor pathway address separate halves of that structure. This relates to normal connective tissue composition and is not a claim about a joint condition.

Aggrecan monomers attach to a hyaluronan filament to form the large aggregates that hold water in cartilage. Hyaluronan supplies that filament, and sulfation of the attached chains depends on the body's sulfate supply. The pairing is structural complementarity rather than a measured interaction.

Boswellic acids act on lipid signalling enzymes, while a methyl-donor compound acts through transmethylation and sulfur metabolism. Because the routes do not overlap, a combination is plausible rather than redundant. There is no combination trial in this candidate set, so this row sits at early confidence.

Curcumin is a substrate for catechol-O-methyltransferase, an enzyme that consumes S-adenosylmethionine and produces S-adenosylhomocysteine. Co-ingesting a methylated catechol substrate and a methyl donor is therefore a real point of contact, and it could pull in either direction depending on the size of each. Nothing in this candidate set measures it.

Tryptophan is hydroxylated and decarboxylated to serotonin, and downstream monoamine methylation consumes S-adenosylmethionine. Combining a serotonin precursor with a methyl donor stacks two inputs to the same neurotransmitter system, which is a reason to be deliberate rather than casual about pairing them. Anyone taking a serotonergic medicine should raise the combination with their prescriber first.

BHMT holds a catalytic zinc that activates the homocysteine thiol for methyl transfer from betaine. Methionine regenerated by that route is the substrate MAT uses to remake S-adenosylmethionine. Zinc adequacy is therefore a structural requirement of the betaine arm of the cycle, independent of the folate arm.